Add Imperial College paper on the VOC (UK variant)

ljl-covid · Jan 1, 2021 · cc06296 · cc06296
1 parent 5619f4b
commit cc06296
Showing 1 changed file with 1 addition and 1 deletion.
diff --git a/README.md b/README.md
@@ -439,7 +439,7 @@ There is mixed advice on the use of masks by the general public, and the advice
 * [Experimental COVID-19 vaccine safe, generates immune response](https://www.nih.gov/news-events/news-releases/experimental-covid-19-vaccine-safe-generates-immune-response) in the NIH-sponsored Phase 1 trial tested mRNA vaccine co-developed with Moderna
 * [Denmark to restrict North Jutland borders due to mink coronavirus outbreak](https://www.thelocal.dk/20201105/denmark-to-restrict-north-jutland-borders-due-to-mink-coronavirus-outbreak) from [a mutated strain that may be less susceptible to current antibodies or vaccines](https://blogs.sciencemag.org/pipeline/archives/2020/11/05/dont-make-mine-mink)
 * [SARS-CoV-2 spike mutations arising in Danish mink and their spread to humans], preliminary paper by the Danish Statens Serum Institut on the mink strains and human spill-back, following an earlier [WHO statement on the matter](https://www.who.int/csr/don/06-november-2020-mink-associated-sars-cov2-denmark/en/) and later a [risk assessment paper by the ECDC](https://www.ecdc.europa.eu/en/publications-data/detection-new-sars-cov-2-variants-mink)
-* [COG-UK update on SARS-CoV-2 Spike mutations of special interest](https://www.cogconsortium.uk/wp-content/uploads/2020/12/Report-1_COG-UK_19-December-2020_SARS-CoV-2-Mutations.pdf) comes after the [UK government announces a mutation](https://www.reuters.com/article/uk-health-coronavirus-britain-strain/uk-says-new-coronavirus-strain-is-more-infectious-but-vaccines-should-still-work-idUSKBN28T0KL) gaining prevalence in South-East England, including London, which appears to spread more easily than pre-existing ones, according to [the government's NERVTAG meeting on SARS-CoV-2 variant under investigation VUI-202012/01](https://khub.net/documents/135939561/338928724/SARS-CoV-2+variant+under+investigation%2C+meeting+minutes.pdf/962e866b-161f-2fd5-1030-32b6ab467896?t=1608470511452), and as shown in a [Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563); the ECDC released a report on this variant on December 20, [Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom](https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf)
+* [COG-UK update on SARS-CoV-2 Spike mutations of special interest](https://www.cogconsortium.uk/wp-content/uploads/2020/12/Report-1_COG-UK_19-December-2020_SARS-CoV-2-Mutations.pdf) comes after the [UK government announces a mutation](https://www.reuters.com/article/uk-health-coronavirus-britain-strain/uk-says-new-coronavirus-strain-is-more-infectious-but-vaccines-should-still-work-idUSKBN28T0KL) gaining prevalence in South-East England, including London, which appears to spread more easily than pre-existing ones, according to [the government's NERVTAG meeting on SARS-CoV-2 variant under investigation VUI-202012/01](https://khub.net/documents/135939561/338928724/SARS-CoV-2+variant+under+investigation%2C+meeting+minutes.pdf/962e866b-161f-2fd5-1030-32b6ab467896?t=1608470511452), which dubs it "Variant of Concern 202012/01" (VOC), and as shown in a [Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563); the ECDC released a report on this variant on December 20, [Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom](https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf), and London's Imperial College later released a report on [Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data](https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-42-sars-cov-2-variant/)
 * [Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against) in a press release where they state that their BNT162b2 vaccine has more than 90% efficacy, based on 94 participant who got COVID-19 during the trial, without any serious safety concerns; the article [Vaccine Efficacy Data!](https://blogs.sciencemag.org/pipeline/archives/2020/11/09/vaccine-efficacy-data) by Derek Lowe provides an early opinion on these results
 * [Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study](https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy), announces the company in a press release claiming a first interim analysis of 95 COVID cases showed an efficacy of 94.5% for their mRNA-1273 vaccine, and severe cases only in the control arm, during their [COVE Phase 3 trial](https://www.modernatx.com/cove-study)
 * [Oxford University](https://www.ox.ac.uk/news/2020-11-23-oxford-university-breakthrough-global-covid-19-vaccine) and [AstraZeneca](https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/azd1222hlr.html) both issue press releases on interim efficacy assessment of their ChAdOx1 nCoV-2019 vaccine, showing overall 70% efficacy but divided into 62% for a group that received two full doses, and 90% for a group receiving a half dose followed by a full-dose booster, and Derek Lowe discusses these results and the methodological differences compared to Pfizer and Moderna in [Oxford/AZ Vaccine Efficacy Data](https://blogs.sciencemag.org/pipeline/archives/2020/11/23/oxford-az-vaccine-efficacy-data)